UK MHRA Warns GLP-1 Users of Pancreatitis Risk

The United Kingdom===Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning to users of GLP-1 medications, including Semaglutide, Semaglutide, and Tirzepatide, about a rare but potentially serious side effect: acute pancreatitis. An estimated 1.6 million adults in England, Wales, and Scotland are thought to have used these drugs. The MHRA has updated product information for healthcare professionals and patients, urging them to be aware of symptoms such as severe, persistent stomach pain that may radiate to the back, accompanied by nausea and vomiting, and to seek immediate medical attention if experienced. Dr Alison Cave, MHRA's Chief Safety Officer, emphasized that while the risk is very small, patient safety is a top priority. The agency encourages reporting of suspected side effects through its Yellow Card scheme. Despite the warning, GLP-1s are generally considered safe and effective for their authorized uses, which include treating type 2 diabetes, weight management, and cardiovascular risk reduction.